borderline significantP = .07
DNMT3A showed a borderline significant ( P = .07) excess burden of pLoF variants among glioma cases and SMAD4 ( P = .06) burden of missense + pLoF variants ( Table S7 ).
DNMT3A showed a borderline significant ( P = .07) excess burden of pLoF variants among glioma cases and SMAD4 ( P = .06) burden of missense + pLoF variants ( Table S7 ).